Intranasal sedation using ketamine and midazolam for pediatric dental treatment (NASO): study protocol for a randomized controlled trial

Trials

Geovanna de Castro Morais Machado¹  Patrícia Corrêa-Faria¹  Analya Rodrigues Miranda¹  Anelise Daher¹  Heloisa Sousa Gomes¹  Karolline Alves Viana¹  Liliani Aires Candido Vieira²  Luciane Rezende Costa²  Paulo Sucasas Costa³  Aline Carvalho Batista⁴  Joji Sado-Filho⁵  Marie Therese Hosey⁶ 

[1] Dentistry Graduate Program, Faculdade de Odontologia (FO), Universidade Federal de Goiás (UFG);Department of Oral Health, FO/UFG;Department of Pediatrics, Faculdade de Medicina (FM), UFG;Department of Stomatology (Oral Pathology), FO/UFG;Health Sciences Graduate Program, FM/UFG;Pediatric Dentistry, Division of Population and Patient Health, King’s College London Dental Institute;

关键词: Dental care for children;    Conscious sedation;    Child behavior;    Midazolam;    Ketamine;    Administration intranasal;   

DOI  :  10.1186/s13063-017-1919-2

来源: DOAJ

【 摘 要 】

Abstract Background Uncooperative children may need to receive dental treatment under sedation, which is indicated when nonpharmacological behavior guidance is unsuccessful. There are randomized controlled trials (RCTs) comparing different sedative protocols for dental procedures; however, the evidence for superiority of one form over another is weak. The primary aim of this study is to investigate the efficacy of intranasally administered ketamine plus midazolam for the dental treatment of children. Methods We have designed a three-armed, parallel RCT to assess intranasal sedation using ketamine/midazolam in terms of the following measures: efficacy, safety, and cost-effectiveness. Two- to 6-year-old healthy children, referred for dental treatment in a dental sedation center in Brazil due to uncooperative behavior and requiring restorative dental procedures, will be recruited. Each child will be randomly assigned to one of the three groups: A – Intranasal administration of ketamine (4.0 mg/kg, maximum 100 mg) and midazolam (0.2 mg/kg, maximum 5.0 mg); B – Oral administration of ketamine (4.0 mg/kg, maximum 100 mg) and midazolam (0.5 mg/kg, maximum 20 mg); and C – Oral administration of midazolam (1.0 mg/kg, maximum 20 mg). The primary outcome is the child’s behavior assessed through an observational scale using digital videos of the restorative dental treatment under sedation. The secondary outcomes are as follows: acceptance of sedative administration; memory of intraoperative events; the child’s stress; adverse events; the child’s pain during the procedure; the parent’s, dentists’, and child’s perceptions of sedation; and economic analysis. Measures will be taken at baseline and drug administration and during and after the dental procedure. The necessary sample size was estimated to be 84 children after a blinded interim analysis of the first 30 cases. Discussion This study will provide data that can substantially add to science and pediatric dentistry as it examines the effect of sedative regimes from different perspectives (outcomes). Trial registration ClinicalTrials.gov, identifier: NCT02447289 . Registered on 11 May 2015, named “Midazolam and Ketamine Effect Administered Through the Nose for Sedation of Children for Dental Treatment (NASO).”

【 授权许可】

Unknown